
Our Approach & Strategy - Orna Therapeutics
Orna has pioneered the creation of novel LNP delivery solutions that are simple, scalable and reach parts of the body other than the liver – the holy grail of RNA delivery. Our approach includes two delivery platforms: panCAR™, which targets multiple lineages of the immune system at once, and SiTu Editing in the Marrow (STEM)™, which ...
Orna Therapeutics Establishes Strategic Collaboration with Vertex ...
Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA ®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna’s circular RNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation ...
Ciaran Lawlor, Ph.D. - Orna Therapeutics
ORNA is a registered trademark, and Orna logo, OROBOROS, panCAR™, FoRCE™ and SiTu Editing in the Marrow (STEM)™ are trademarks of Orna Therapeutics, Inc.
Melanie Morel-Ferris - Orna Therapeutics
ORNA is a registered trademark, and Orna logo, OROBOROS, panCAR™, FoRCE™ and SiTu Editing in the Marrow (STEM)™ are trademarks of Orna Therapeutics, Inc.
Amit Munshi - Orna Therapeutics
ORNA is a registered trademark, and Orna logo, OROBOROS, panCAR™, FoRCE™ and SiTu Editing in the Marrow (STEM)™ are trademarks of Orna Therapeutics, Inc.
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next ...
Orna will retain rights to its oRNA-LNP technology platform and will continue to advance other wholly owned programs in areas such as oncology and genetic disease. Merck will also invest $100 million of equity in Orna’s recently completed Series B financing round.
Orna Therapeutics Appoints Nobel Laureate Carolyn Bertozzi, …
WATERTOWN, Mass., July 30, 2024 – Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines, including panCAR™ in vivo CAR therapies for oncology and autoimmune diseases, today announced the appointment of Carolyn Bertozzi, Ph.D., a 2022 Nobel Laureate in Chemistry, as Co-Chair of ...
ReNAgade Therapeutics Launches with Over $300 Million in Series …
Joint Venture with Orna Therapeutics combines foundational ReNAgade delivery technology with circular RNA to discover and develop programs supporting a major collaboration with Merck
Simcere - Orna Therapeutics
ORNA is a registered trademark, and Orna logo, OROBOROS, panCAR™, FoRCE™ and SiTu Editing in the Marrow (STEM)™ are trademarks of Orna Therapeutics, Inc.
Novartis - Orna Therapeutics
ORNA is a registered trademark, and Orna logo, OROBOROS, panCAR™, FoRCE™ and SiTu Editing in the Marrow (STEM)™ are trademarks of Orna Therapeutics, Inc.